Author

J. M. Swain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:host-pathogen & immune response· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

D. MURIAUX· 3 shared P. Merida· 2 shared S. Lyonnais· 2 shared A. Makinson· 1 shared A. Mouttou· 1 shared A. Neyret· 1 shared C. Arone· 1 shared C. B. Chesnais· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

D. MURIAUX

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BiochemistrybioRxivPreprintMar 13, 2023

Specific targeting and clustering of Phosphatidylserine lipids by RSV M protein is critical for virus particle production

J. M. Swain, M. Bierre, L. Veyrie…·M. Bajorek

This study shows RSV M protein binds phosphatidylserine lipids, promoting viral assembly, and identifies lipid interactions critical for virus production.

DOI 10.1101/2023.03.13.532372

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintMar 23, 2022

Optimized production and fluorescent labelling of SARS-CoV-2 Virus-Like-Particles to study virus assembly and entry.

D. Muriaux, M. Gourdelier, J. M. Swain…·C. Favard

This paper optimizes the production of SARS-CoV-2 Virus-Like Particles (VLPs) and demonstrates their fluorescent labeling for studying virus assembly and entry mechanisms.

DOI 10.1101/2022.03.23.485575

humanexperimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintNov 1, 2021

Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.

C. Chable-Bessia, C. Boulle, A. Neyret…·D. Muriaux

This study evaluates the anti-SARS-CoV-2 activity of ivermectin and other macrocyclic lactones in vitro, finding low selectivity indices that suggest limited therapeutic potential for COVID-19.

DOI 10.1101/2021.11.01.466865

humanbulk RNA-seq

𝕏 PostBluesky